C

Clarity Pharmaceuticals Ltd
ASX:CU6

Watchlist Manager
Clarity Pharmaceuticals Ltd
ASX:CU6
Watchlist
Price: 3.36 AUD 5.33% Market Closed
Market Cap: 1.3B AUD

Intrinsic Value

The intrinsic value of one CU6 stock under the Base Case scenario is 0.5 AUD. Compared to the current market price of 3.36 AUD, Clarity Pharmaceuticals Ltd is Overvalued by 85%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CU6 Intrinsic Value
0.5 AUD
Overvaluation 85%
Intrinsic Value
Price
C
Base Case Scenario

Valuation History
Clarity Pharmaceuticals Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about CU6?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CU6 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Clarity Pharmaceuticals Ltd.

Explain Valuation
Compare CU6 to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Clarity's success hinges on its unproven copper-based radiopharmaceuticals; any unexpected safety issues or lack of efficacy data from ongoing clinical trials could significantly undermine investor confidence and jeopardize future funding.

The company’s focus on highly specialized radiopharmaceuticals exposes it to elevated supply chain risks, particularly in securing isotope production and handling. Even minor disruptions can delay R&D timelines and erode Clarity’s competitive advantage.

Heightened competition from established radiotherapy players with larger R&D budgets and deeper commercialization experience may overshadow Clarity’s marketing efforts, slowing adoption and limiting its share in the growing nuclear medicine market.

Bull Theses

Clarity’s copper-based radiopharmaceutical platform offers a differentiated approach with the potential for improved diagnostic accuracy and therapeutic effectiveness, putting it at the forefront of next-generation radiotherapy innovation.

The company’s expanding oncology pipeline, targeting multiple cancer indications with precisely targeted nuclear therapies, could open up significant revenue opportunities if pivotal trial results prove robust and lead to regulatory approvals.

Strategic collaborations with leading academic institutes and hospitals help accelerate Clarity’s clinical development process and strengthen its credibility, potentially translating into faster market adoption and enhanced brand recognition.

Show More Less
How do you feel about CU6?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Clarity Pharmaceuticals Ltd

Balance Sheet Decomposition
Clarity Pharmaceuticals Ltd

Current Assets 100.6m
Cash & Short-Term Investments 84.1m
Receivables 10.1m
Other Current Assets 6.4m
Non-Current Assets 566k
PP&E 552.5k
Other Non-Current Assets 13.5k
Current Liabilities 10.4m
Accounts Payable 3.2m
Accrued Liabilities 2.5m
Other Current Liabilities 4.7m
Non-Current Liabilities 561.8k
Other Non-Current Liabilities 561.8k
Efficiency

Free Cash Flow Analysis
Clarity Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Clarity Pharmaceuticals Ltd

Revenue
0 AUD
Operating Expenses
-69.1m AUD
Operating Income
-69.1m AUD
Other Expenses
4.8m AUD
Net Income
-64.3m AUD
Fundamental Scores

CU6 Profitability Score
Profitability Due Diligence

Clarity Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Negative 3Y Average Net Margin
Negative 3Y Average Operating Margin
Negative ROE
23/100
Profitability
Score

Clarity Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

CU6 Solvency Score
Solvency Due Diligence

Clarity Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Clarity Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CU6 Price Targets Summary
Clarity Pharmaceuticals Ltd

Wall Street analysts forecast CU6 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CU6 is 7.55 AUD with a low forecast of 5.05 AUD and a high forecast of 9.66 AUD.

Lowest
Price Target
5.05 AUD
50% Upside
Average
Price Target
7.55 AUD
125% Upside
Highest
Price Target
9.66 AUD
188% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Clarity Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for CU6 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CU6 stock?

The intrinsic value of one CU6 stock under the Base Case scenario is 0.5 AUD.

Is CU6 stock undervalued or overvalued?

Compared to the current market price of 3.36 AUD, Clarity Pharmaceuticals Ltd is Overvalued by 85%.

Back to Top